Allosteric modulation of sigma‐1 receptors elicits anti‐seizure activities
- 26 June 2015
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (16) , 4052-4065
Abstract
Background and Purpose: Application of orthosteric sigma‐1 receptor agonists as anti‐seizure drugs has been hindered by questionable efficacy and potential adverse effects. Here, we have investigated the anti‐seizure effects of the novel and potent allosteric modulator of sigma‐1 receptors, SKF83959 and its derivative SOMCL‐668 (3‐methyl‐phenyl‐2,3,4,5‐tetrahydro‐1H‐benzo[d]azepin‐7‐ol).Experimental Approach: The anti‐seizure effects of SKF83959 were investigated in three mouse models, maximal electroshock seizures, pentylenetetrazole‐induced convulsions and kainic acid‐induced ‘status epilepticus’. Also, in rats, the cortical epileptiform activity induced by topical application of picrotoxin was recorded in electrocorticograms. In rat hippocampal brain slices, effects of the drugs on the high potassium‐evoked epileptiform local field potentials were studied. Anti‐seizure activities of SOMCL‐668, a newly developed sigma‐1 receptor selective allosteric modulator, were also investigated.Key Results: SKF83959 (20, 40 mg·kg−1) exhibited anti –seizure actitity in the three mouse models and reduced the cortical epileptiform activity without alteration of spontaneous motor activity and motor coordination. These effects were blocked by the sigma‐1 receptor antagonist BD1047, but not the dopamine D1 receptor antagonist SCH23390. SKF83959 alone did not directly inhibit the epileptiform firing of CA3 neurons induced by high potassium in hippocampal slices, but did potentiate inhibition by the orthosteric sigma‐1 receptor agonist SKF10047. Lastly, a selective sigma‐1 receptor allosteric modulator SOMCL‐668, which does not bind to dopamine receptors, exerted similar anti‐seizure activities.Conclusions and Implications: SKF83959 and SOMCL‐668 displayed anti‐seizure activities, indicating that allosteric modulation of sigma‐1 receptors may provide a novel approach for discovering new anti‐seizure drugs.Keywords
Funding Information
- National Science Foundation of China (81402905, 81130023, 30825042)
- National Basic Research Plan (973) of the Ministry of Science and Technology of China (2011CB504403)
- Priority Academic Program Development of Jiangsu Higher Education Institute (PAPD)
- Jiangsu Key Laboratory (BM2013003)
This publication has 49 references indexed in Scilit:
- SKF83959 Is a Potent Allosteric Modulator of Sigma-1 ReceptorMolecular Pharmacology, 2013
- Cannabidivarin is anticonvulsant in mouse and ratBritish Journal of Pharmacology, 2012
- Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Behavioural phenotyping of knockout mice for the sigma-1 (σ1) chaperone protein revealed gender-related anxiety, depressive-like and memory alterationsJournal of Psychopharmacology, 2011
- The sigma-1 receptor chaperone as an inter-organelle signaling modulatorTrends in Pharmacological Sciences, 2010
- Electrophysiological Effects of SKF83959 on Hippocampal CA1 Pyramidal Neurons: Potential Mechanisms for the Drug's Neuroprotective EffectsPLOS ONE, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- The pharmacology of sigma-1 receptorsPharmacology & Therapeutics, 2009
- Carbetapentane attenuates kainate-induced seizures via σ-1 receptor modulationLife Sciences, 2001